D-0526-2025 Class III Ongoing

Recalled by Orient Pharma Co., Ltd. Yunlin Plant — Yunlin County

FDA drug recall D-0526-2025 was initiated by Orient Pharma Co., Ltd. Yunlin Plant on Jun 11, 2025 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is ongoing. Affected quantity: 57504 bottles.

Recall details

Product Type
Drugs
Report Date
Jul 9, 2025
Initiation Date
Jun 11, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
57504 bottles

Product description

Pitavastatin Tablets, 2 mg, Rx Only, 90 Tablets, Manufactured by: Orient Pharma Co., Ltd., 8 Kehu 1st Road, Huwei Chen, Yunlin, Taiwan, 63247, Manufactured for: Teva Pharmaceuticals, Parsippany, NJ 07054, Product of Taiwan, NDC 0480-3632-98.

Reason for recall

Failed Impurities/Degradation Specifications.

Distribution pattern

NJ

Code information

P061001, P061002, P061003, P061004, P061006 & P061007 Exp Date 07/2025; P061008, Exp Date 08/2025; P061009 & P061010 Exp Date 10/2025; P061011, P061012 & P061013 Exp Date 01/2026; P061016, P061017 & P061018, Exp Date 04/2026; P061019, Exp Date 05/2026; P061023, Exp Date 01/2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0526-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0526-2025. Report a data issue: hello@regdatalab.com.